ESC Professional Premium Access

Inhibition of liver ApoC3 by GalNAc-conjugated siRNA RBD5044: first-in-human trial to evaluate the safety, pharmacokinetics (PK), and pharmacodynamic (PD) effects on atherogenic lipid profiles in heal

Congress Presentation

About the speaker

Associate Professor Anders Gabrielsen

Ribocure Pharmaceuticals, Gothenburg (Sweden)
1 follower

7 more presentations in this session

The differences in lipid lowering therapies and the LDL-C goal attainment in patients with ASCVD documented by cardiologists and general practitioners in Germany.

Speaker: Professor O. Weingaertner (Jena, DE)

Thumbnail

Icosapent ethyl reduces cardiovascular risk across apolipoprotein b and fasting triglyceride rich lipoprotein levels

Speaker: Doctor W. Malick (New York City, US)

Thumbnail

Efficacy and safety of quadruple-drug fixed-dose single-pill combination therapy for hypertension and dyslipidemia: a prospective, multicenter, observational study

Speaker: Assistant Professor E. Park (Seoul, KR)

Thumbnail

Long-term survival of heFH or ACS patients on PCSK9 targeted therapy based on the real-life data from poland

Speaker: Professor M. Banach (Lodz, PL)

Thumbnail

Safety and efficacy of obicetrapib in dyslipidemia: systematic review and meta-analysis

Speaker: Mr A. Senk Juh (Logatec, SI)

Thumbnail

Access the full session

Novel insights into lipid-lowering pharmacotherapy

Speakers: Associate Professor A. Gabrielsen, Professor O. Weingaertner, Doctor W. Malick, Assistant Professor E. Park, Professor M. Banach...
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations